Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual ... Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.44 | -10.0456621005 | 4.38 | 4.5999 | 3.5801 | 56227 | 3.93904228 | CS |
4 | 0.27 | 7.35694822888 | 3.67 | 4.65 | 3.5801 | 30002 | 3.87722561 | CS |
12 | -0.1 | -2.47524752475 | 4.04 | 5.0899 | 3.5601 | 19316 | 3.99132915 | CS |
26 | 0.24 | 6.48648648649 | 3.7 | 5.2 | 2.78 | 15489 | 3.90798573 | CS |
52 | 0.74 | 23.125 | 3.2 | 5.2 | 2.78 | 10494 | 3.90482516 | CS |
156 | -11.36 | -74.2483660131 | 15.3 | 15.7 | 2.40101 | 57901 | 8.53029382 | CS |
260 | -6.66 | -62.8301886792 | 10.6 | 56.8 | 2.40101 | 699510 | 26.87963785 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.